All In Biotech

Drug Trial Radar · NCT07832201

A Phase IV Clinical Trial of Influenza Vaccine (Split Virion), Inactivatedin (Anflu®) Pregnant Women (AnFLU-PREG)

A Phase IV, Randomized, Double-blind, Positive-controlled , Multicenter Clinical Trial to Evaluate the Immunogenicity and Safety of Influenza Vaccine (Split Virion) , Inactivated (Anflu®) in Pregnant Women

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Oct 20, 2026

Primary completion

Feb 2027

Study completion Apr 2027

Sponsor

Lead sponsor
Sinovac Biotech Co., LtdIndustry
Sponsor type
Industry
First posted
Sep 21, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A phase IV clinical trial of Influenza Vaccine (Split Virion), Inactivated (Anflu®) developed by Sinovac Biotech Co., Ltd will be conducted in pregnant women. A total of 150 healthy pregnant women aged 18\~45 years at 22 to 34 weeks (+6 days) of pregnancy will be enrolled. All participants will be randomized to test group and control group in a ratio of 2:1 and receive one dose of vaccine (0.5 mL) of Sinovac Influenza Vaccine (Split Virion) , Inactivated (Anflu®) or Sanofi VAXIGRIP®, respectively.

Conditions

  • Influenza

Interventions

  • Anflu®Biological

    Participants will receive one dose of Sinovac Anflu® .

  • Vaxigrip®Biological

    Participants will receive one dose of Sanofi Vaxigrip®.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The seroconversion rates (SCRs) of hemagglutination inhibition (HI) antibodies at day 28 ,as measured by HAI assay for vaccine-matched influenza A and BTime frame: 28 days after vaccination
  2. Incidence of adverse reactions within 28 days after vaccinationTime frame: 28 days after vaccination

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Hunan Provincial Maternal and Child Health Care Hospital

    Changsha, China · Recruiting

  • Chengdu Women's and Children's Central Hospital

    Chengdu, China · Recruiting

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, China · Recruiting

  • Nanfang Hospital, Southern Medical University

    Guangzhou, China · Recruiting

  • Nanjing Drum Tower Hospita

    Nanjing, China · Recruiting

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.